我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

比索洛尔对高血压病并发慢性心力衰竭患者脑钠尿肽前体的影响

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2016年第6期
页码:
694-696,700
栏目:
临床研究
出版日期:
2016-07-05

文章信息/Info

Title:
Effect of bisoprolol on ProBNP in patients with hypertension combined with chronic heart failure
作者:
周 亮; 葛坤文; 钟太敏
（高州市金山医院内科，广东 高州 525259）
Author(s):
ZHOU Liang;  GE Kun-wen;  ZHONG Tai-min
(Department of Internal Medicine, Jinshan Hospital, Caozhou 525259, Guangdong, China)
关键词:
比索洛尔; 高血压; 原发性; 心力衰竭; 慢性; 脑钠尿肽前体
Keywords:
bisoprolol;  hypertension;  chronic heart failure;  BNP precursor
分类号:
R544.1
DOI:
-
文献标识码:
A
摘要:
目的 探讨比索洛尔对高血压病并发慢性心力衰竭（CHF）患者脑钠尿肽（BNP）前体（Pro-BNP)的影响。方法 选取我院收治的高血压病并发CHF的患者102例，随机分为试药组和对照组各51例。对照组按照高血压病并发CHF的常规治疗方案进行干预，试药组在对照组治疗方案的基础上，加用比索洛尔口服治疗。治疗3个月后对比两组患者的心功能改善情况，同时对比两组患者治疗前后的心率、血压、左室射血分数(LVEF)以及pro-BNP的变化情况。结果 试药组的显效率为49%，总有效率为96%，均显著高于对照组（分别为29%，76%，均P<0.05）；两组患者治疗后的心率、收缩压和舒张压均显著低于治疗前，而LVEF显著高于治疗前（均P<0.05）；试药组治疗后的LVEF为（44±4）%，显著高于对照组〔（35±4）%，P<0.05〕；试药组治疗后的Pro-BNP水平为（733±58） ng/L，对照组治疗后的Pro-BNP水平为（802±63） ng/L，两组患者治疗后的Pro-BNP水显著低于治疗前（均P<0.05）；试药组治疗后的Pro-BNP水平显著低于对照组（P<0.05）。结论 比索洛尔可有效降低高血压病并发CHF患者的Pro-BNP水平，提高临床疗效。
Abstract:
AIM To investigate the effects of bisoprolol on brain natriuretic peptide (BNP) in patients with hypertension combined with chronic heart failure (CHF) and to provide a theoretical basis for the formulation of clinical treatment. METHODSOne hundred and two hypertensive patients combined with CHF in our hospital were randomly divided into observation group and control group (51 cases in each group). The control group received conventional treatment and the observation group received conventional treatment plus bisoprolol. After 3 months of treatment, improvement of heart function of the two groups was compared and changes of heart rate, blood pressure, left ventricular ejection fraction and BNP before and after treatment were also compared between groups. RESULTSThe total effective rate in the observation group was 96.08%, significantly higher than in the control group (P<0.05). In both groups, heart rate, systolic blood pressure and diastolic blood pressure were significantly lower, whereas left ventricular ejection fraction was significantly higher than before treatment (P<0.05). Left ventricular ejection fraction in observation group was significantly higher than in control group. BNP levels in both groups decreased markedly after treatment (both P<0.05) and the level in the observation group was significantly lower than the control group (P<0.05). CONCLUSIONBisoprolol can effectively reduce the level of BNP in hypertensive patients combined with CHF, promote curative effects and improve heart function.

参考文献/References

[1]龚厚文,罗兴林.BNP,NT-proBNP检测在心力衰竭中的应用进展[J].西南军医,2010,12(1):99-101.
[2]岳静雯,蒋 利,沈泽宁,等.血BNP监测对慢性心力衰竭患者治疗的指导价值及其对预后的影响研究[J].现代生物医学进展,2012,12(16):3150-3153.
[3]刘大为,刘 星,刘素文,等.β受体阻滞剂治疗老年冠心病、心衰临床观察[J].中国美容医学,2010,19(z1):67-69.
[4]中华医学会心血管病学分会,中华心血管病杂志编辑委员会. 慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2007,35(12):1076-1095.
[5]黄 炜,吴建东.卡维地洛与依那普利联合治疗老年慢性心衰的疗效[J].中国老年学杂志,2011,31(24):4890-4891.
[6]孟 维.国际心力衰竭治疗新进展[J].中国组织工程研究,2014,(z1):298-298.
[7]李明琰,陆东风,何文凯,等.重组人脑利钠肽治疗难治性心力衰竭患者的短期疗效观察[J].实用医学杂志,2012,28(9):1579-1580.
[8]吴同果.血管紧张素转换酶抑制剂治疗慢性心力衰竭的评价[J].岭南心血管病杂志,2012,18(2):108-111.
[9]叶海峰.β受体阻滞剂在心衰治疗中的作用观察[J].医学信息,2014,(8):501-502.
[10]刘爱华,王绪芳,韩桂云,等.脑钠肽和NT-Pro BNP检测在心力衰竭诊断中的意义[J].中国基层医药,2011,18(8):1038-1040.
[11]辛丽娜,严锦贤,陈美华,等.健心颗粒对慢性心衰大鼠循环RAAS系统的影响[J].海峡科学,2010,(5):84-85.

备注/Memo

备注/Memo:
收稿日期：2015-09-11.
作者简介：周亮,副主任医师Email：zhouliangtg@163.com
更新日期/Last Update: 2016-07-10